Part I: Parkin-associated proteins and Parkinson's disease

被引:56
作者
Dev, KK [1 ]
van der Putten, H [1 ]
Sommer, B [1 ]
Rovelli, G [1 ]
机构
[1] Novartis Pharma AG, Nervous Syst Res, Unit Neurodegenerat, CH-4002 Basel, Switzerland
关键词
parkin; ubiquitination; UbcH7/8; PDZ; protein-protein interactions; neurodegeneration; Parkinson's disease; Alzheimer's disease;
D O I
10.1016/S0028-3908(02)00337-4
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Parkin is an E3 ligase that plays an important role in the ubiquitin/proteosome pathway responsible for protein degradation events. Mutations in parkin result in a loss-of-function and lead to Parkinson's disease, a progressive neurological disorder of movement. Presumably, this occurs due to the toxic build-up of proteins that are no longer effectively cleared/degraded by the parkin-dependent ubiqutin/proteosome pathway. To date, three types of proteins have been shown to interact with parkin. Firstly, the E2 ubiquitin conjugating proteins called UbcH7 and UbcH8 interact with parkin. Secondly, putative substrates interacting with parkin include a synaptic vesicle associated GTPase named CDCrel-l; a G protein-coupled receptor named Pael; a novel from of U.-synuclein; and an alpha-synuclein interacting protein synphilin-1. Thirdly and more recently, a PDZ domain containing scaffolding protein CASK/Lin2 has been shown to interact with the PDZ binding motif of parkin. A network of PDZ-interacting proteins has potential to form a complex web of molecules that surround parkin and regulate its subcellular localisation and function. (C) 2003 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:1 / 13
页数:13
相关论文
共 105 条
[61]   Direct binding and functional coupling of α-synuclein to the dopamine transporters accelerate dopamine-induced apoptosis [J].
Lee, FJS ;
Liu, F ;
Pristupa, ZB ;
Niznik, HB .
FASEB JOURNAL, 2001, 15 (06) :916-926
[62]   The ubiquitin pathway in Parkinson's disease [J].
Leroy, E ;
Boyer, R ;
Auburger, G ;
Leube, B ;
Ulm, G ;
Mezey, E ;
Harta, G ;
Brownstein, MJ ;
Jonnalagada, S ;
Chernova, T ;
Dehejia, A ;
Lavedan, C ;
Gasser, T ;
Steinbach, PJ ;
Wilkinson, KD ;
Polymeropoulos, MH .
NATURE, 1998, 395 (6701) :451-452
[63]   Effect of familial Parkinson's disease point mutations A30P and A53T on the structural properties, aggregation, and fibrillation of human α-synuclein [J].
Li, J ;
Uversky, VN ;
Fink, AL .
BIOCHEMISTRY, 2001, 40 (38) :11604-11613
[64]   UBIQUITIN CARBOXYL-TERMINAL HYDROLASE (PGP 9.5) IS SELECTIVELY PRESENT IN UBIQUITINATED INCLUSION-BODIES CHARACTERISTIC OF HUMAN NEURODEGENERATIVE DISEASES [J].
LOWE, J ;
MCDERMOTT, H ;
LANDON, M ;
MAYER, RJ ;
WILKINSON, KD .
JOURNAL OF PATHOLOGY, 1990, 161 (02) :153-160
[65]   Association between early-onset Parkinson's disease and mutations in the parkin gene [J].
Lücking, CB ;
Dürr, A ;
Bonifati, V ;
Vaughan, J ;
De Michele, G ;
Gasser, T ;
Harhangi, BS ;
Meco, G ;
Denèfle, P ;
Wood, NW ;
Agid, Y ;
Brice, A .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 342 (21) :1560-1567
[66]   Alpha-synuclein and Parkinson's disease [J].
Lücking, CB ;
Brice, A .
CELLULAR AND MOLECULAR LIFE SCIENCES, 2000, 57 (13-14) :1894-1908
[67]   Down-regulation of parkin protein in transient focal cerebral ischemia: A link between stroke and degenerative disease? [J].
Mengesdorf, T ;
Jensen, PH ;
Mies, G ;
Aufenberg, C ;
Paschen, W .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (23) :15042-15047
[68]  
Missler M, 1998, J NEUROCHEM, V71, P1339
[69]  
Mizuno Y, 1998, J NEUROCHEM, V71, P893
[70]   A novel transactivation domain in parkin [J].
Morett, E ;
Brok, P .
TRENDS IN BIOCHEMICAL SCIENCES, 1999, 24 (06) :229-231